Frontier drug discovery programs require frontier capabilities. Today, we’re excited to share that BMS will be using Chai’s models to support the discovery of new therapeutics. Since rolling out Chai-3 to partners at the start of this year, we’ve partnered with
@EliLillyandCo,
@Novartis,
@Pfizer,
@argenxglobal, and now
@BMSnews. Many of the world’s leading biopharma companies are now using our models to go after diseases.
Scientific discovery is the domain where access to frontier AI matters the most. At
@ChaiDiscovery, we’ve seen first hand how our latest model generations can make the difference between discovering a molecule and not. We’re excited to work with
@BMSnews to break new ground in medicine and science.